Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network.

Single-agent rituximab as first-line and maintenance treatment for patients with chronic... To assess the efficacy and toxicity of first-line single-agent rituximab, followed by re-treatment with rituximab at 6-month intervals, in previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of clinical oncology : official journal of the American Society of Clinical Oncology Pubmed

Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology , Volume 21 (9): -1694 – May 20, 2003

Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network.


Abstract

To assess the efficacy and toxicity of first-line single-agent rituximab, followed by re-treatment with rituximab at 6-month intervals, in previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Loading next page...
 
/lp/pubmed/single-agent-rituximab-as-first-line-and-maintenance-treatment-for-63n3lYmXWB

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
0732-183X
DOI
10.1200/JCO.2003.09.027
pmid
12721250

Abstract

To assess the efficacy and toxicity of first-line single-agent rituximab, followed by re-treatment with rituximab at 6-month intervals, in previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Journal

Journal of clinical oncology : official journal of the American Society of Clinical OncologyPubmed

Published: May 20, 2003

There are no references for this article.